https://scholars.lib.ntu.edu.tw/handle/123456789/566416
標題: | Randomized open trial comparing 2-dose regimens of the human papillomavirus 16/18 as04-adjuvanted vaccine in girls aged 9-14 years versus a 3-dose regimen in women aged 15-25 years | 作者: | Puthanakit T. LI-MIN HUANG Chiu C.-H. Tang R.-B. Schwarz T.F. Esposito S. Frenette L. Giaquinto C. McNeil S. Rheault P. Durando P. Horn M. Klar M. Poncelet S. De Simoni S. Friel D. De Muynck B. Suryakiran P.V. Hezareh M. Descamps D. Thomas F. Struyf F. |
關鍵字: | 2-dose schedule; Adjuvant System containing 50 ?g 3-O-desacyl-4?-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 ?g Al3+); AS04; Cell-mediated immunity; Cervical cancer; CMI; Geometric mean antibody titer; GMT; HPV; Human papillomavirus; IgG; Immunogenicity | 公開日期: | 2016 | 出版社: | Oxford University Press | 卷: | 214 | 期: | 4 | 起(迄)頁: | 525-536 | 來源出版物: | Journal of Infectious Diseases | 摘要: | Background. This randomized, open trial compared regimens including 2 doses (2D) of human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine in girls aged 9-14 years with one including 3 doses (3D) in women aged 15-25 years. Methods. Girls aged 9-14 years were randomized to receive 2D at months 0 and 6 (M0,6; (n = 550) or months 0 and 12 (M0,12; n = 415), and women aged 15-25 years received 3D at months 0, 1, and 6 (n = 482). End points included noninferiority of HPV-16/ 18 antibodies by enzyme-linked immunosorbent assay for 2D (M0,6) versus 3D (primary), 2D (M0,12) versus 3D, and 2D (M0,6) versus 2D (M0,12); neutralizing antibodies; cell-mediated immunity; reactogenicity; and safety. Limits of noninferiority were predefined as <5% difference in seroconversion rate and <2-fold difference in geometric mean antibody titer ratio. Results. One month after the last dose, both 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6). Geometric mean antibody titer ratios (3D/2D) for HPV-16 and HPV-18 were 1.09 (95% confidence interval, .97-1.22) and 0.85 (.76-.95) for 2D (M0,6) versus 3D and 0.89 (.79-1.01) and 0.75 (.67-.85) for 2D (M0,12) versus 3D. The safety profile was clinically acceptable in all groups. Conclusions. The 2D regimens for the HPV-16/18 AS04-adjuvanted vaccine in girls aged 9-14 years (M0,6 or M0,12) elicited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years. ? The Author 2016. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84988975003&doi=10.1093%2finfdis%2fjiw036&partnerID=40&md5=99abbb325733e3c2df8452a6ba743244 https://scholars.lib.ntu.edu.tw/handle/123456789/566416 |
ISSN: | 0022-1899 | DOI: | 10.1093/infdis/jiw036 | SDG/關鍵字: | neutralizing antibody; Wart virus vaccine; aluminum hydroxide; ASO4 mixture; immunological adjuvant; lipid A; neutralizing antibody; virus antibody; Wart virus vaccine; adolescent; adult; antibody titer; Article; B lymphocyte; CD4+ T lymphocyte; cellular immunity; child; controlled study; cross reaction; dosage schedule comparison; drug dose regimen; drug safety; enzyme linked immunosorbent assay; fatigue; female; fever; headache; human; Human papillomavirus type 16; Human papillomavirus type 18; Human papillomavirus type 31; Human papillomavirus type 45; immune response; immunogenicity; injection site pain; memory cell; myalgia; nerve paralysis; normal human; open study; phase 3 clinical trial; priority journal; randomized controlled trial; reactogenicity; seroconversion; swelling; urticaria; vaccination; age; analogs and derivatives; blood; comparative study; immunization; immunology; Papillomavirus Infections; treatment outcome; young adult; Adjuvants, Immunologic; Adolescent; Age Factors; Aluminum Hydroxide; Antibodies, Neutralizing; Antibodies, Viral; Child; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; Immunization Schedule; Lipid A; Papillomavirus Infections; Papillomavirus Vaccines; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。